Hence in the current research, the associations between clinical characteristics and effectiveness of anti-PD-1 inhibitors in advanced NSCLC patients harboring EGFR sensitive mutations were investigated within a retrospective real-world approach. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.